Achondroplasia (AP), hypochondroplasia (HP), and thanatophoric dysplasia (TD) are among the most common skeletal dysplasias.
Epidemiology
Incidence
Achondroplasia – 1/15,000-1/20,000 live births
Hypochondroplasia – 1/15,000-1/40,000 live births
Thanatophoric dysplasia – 1/6,500-20,000 live births
Sex – equal distribution
Inheritance
Autosomal dominant, mostly de novo mutations in TD, with 100% penetrance
Cause – fibroblast growth factor receptor 3 (FGFR3) gene mutations
AP
99% of cases result from substitution of A or C nucleotide for G at 1138 in the FGFR3 gene
HP
70% of cases result from substitution of A or G nucleotide for C at 1620 in the FGFR3 gene
TD
Eleven FGFR3 mutations (6 missense and 5 read-throughs of the native stop codon) cause 99% of TDI
A single FGFR3 mutation, K650E, is responsible for TDII
Recurrence risk in offspring – for phenotypically normal parents with a previously affected pregnancy, the recurrence risk is not increased over the general population
Pathophysiology
All mutations result in gain of FGFR3 function capable of initiating intracellular signal pathways in the absence of ligand binding, leading to premature differentiation of proliferative chondrocytes and premature bone maturation
Clinical Presentation
All have a large head; shortening of long bones and/or short stature
AP
Shortened long bones fall below the 5th percentile by the third trimester of pregnancy
Frontal bossing, midface hypoplasia
Trident appearance of hands; pronounced lumbar lordosis
Mean adult height 48-52 inches for female and males respectively
Normal intelligence
HP
Short stature of postnatal onset, usually evident by 3 years of age
Lack of facial dysmorphism
Adult height ranges from 47 to 60 inches
Ten percent have mental deficiency
TD
Shortened long bones with onset in the early second trimester of pregnancy
Typically lethal in neonatal period from brain stem compression and pulmonary hypoplasia
Mutations tested: c.742C>T, c.746C>G, c.1108G>T, c.11A>T, c.1118A>G, c.2419T>G, c.2419T>A, c.2420G>T, c.2420G>C, c.2421A>T, c.2421A>C and c.2421A>G in TDI and c.1948A>G in TDII
Mutations other than those targeted in FGFR3 will not be detected; specificity may be compromised by rare primer site mutations; clinical and analytic sensitivity is 99%
Thanatophoric Dysplasia, Types I and II (FGFR3) 13 Mutations, Fetal 0051508
Mutations tested: c.742C>T, c.746C>G, c.1108G>T, c.1111A>T, c.1118A>G, c.2419T>G, c.2419T>A, c.2420G>T, c.2420G>C, c.2421A>T, c.2421A>C and c.2421A>G in TDI and c.1948A>G in TDII
Mutations other than those targeted in FGFR3 will not be detected; specificity may be compromised by rare primer site mutations; clinical and analytic sensitivity is 99%
Method: Polymerase Chain Reaction/Fluorescent Resonance Energy Transfer
Mutations tested: c.1138G>A, c.1138G>C
Mutations other than c.1138G>A and c.1138G>C will not be detected; clinical and analytic sensitivity is 99%
General References
Carter EM, Davis JG, Raggio CL.Advances in understanding etiology of achondroplasia and review of management.Curr Opin Pediatr. 2007;19(1):32-37. (Link to PubMed)
Cohen MM Jr.Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level.Int J Oral Maxillofac Surg. 1998;27(6):451-455. (Link to PubMed)
Horton WA, Hall JG, Hecht JT.Achondroplasia.Lancet. 2007;370(9582):162-172. (Link to PubMed)
Horton WA.Molecular genetic basis of the human chondrodysplasias.Endocrinol Metab Clin North Am. 1996;25(3):683-697. (Link to PubMed)
Langer LO Jr, Yang SS, Hall JG, Sommer A, Kottamasu SR, Golabi M, Krassikoff N.Thanatophoric dysplasia and cloverleaf skull.Am J Med Genet Suppl. 1987;3:167-179. (Link to PubMed)
Lemyre E, Azouz EM, Teebi AS, Glanc P, Chen MF.Bone dysplasia series. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: review and update.Can Assoc Radiol J. 1999;50(3):185-197. (Link to PubMed)
Mortier GR.The diagnosis of skeletal dysplasias: a multidisciplinary approach.Eur J Radiol. 2001;40(3):161-167. (Link to PubMed)
Neumann L, Kunze J, Uhl M, Stover B, Zabel B, Spranger J.Survival to adulthood and dominant inheritance of platyspondylic skeletal dysplasia, Torrance-Luton type.Pediatr Radiol. 2003;33(11):786-790. (Link to PubMed)
Savarirayan R, Rimoin DL.The skeletal dysplasias.Best Pract Res Clin Endocrinol Metab. 2002;16(3):547-560. (Link to PubMed)
Unger S.A genetic approach to the diagnosis of skeletal dysplasia.Clin Orthop Relat Res. 2002;(401):32-38. (Link to PubMed)
Williams CJ, Jimenez SA.Skeletal dysplasias and the osteoarthritic phenotype.Best Pract Res Clin Rheumatol. 2003;17(6):1005-1018. (Link to PubMed)
Reviewed by
Lyon, Elaine, Ph.D. Medical Director, Molecular Genetics at ARUP Laboratories; Associate Professor, Pathology, University of Utah
Mao, Rong , M.D. Co-Medical Director, Molecular Genetics at ARUP Laboratories; Assistant Professor, Pathology, University of Utah
Comprehensive Review: May 2008
Last Update: May 2008